---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-23-000011"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2023-01-31T23:59:59+00:00"
generated_at: "2026-06-20T05:48:40.913826+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amgen posts flat Q4 revenue $6.8B, GAAP EPS down 11%; FTC extends HSR review for Horizon deal

## Summary
- GAAP EPS $3.00 (down 11% YoY); non-GAAP EPS $4.09 (down 7% YoY).
- Total revenue $6.8B unchanged; product sales +4% with 10% volume growth.
- Full year 2022 revenue $26.3B (+1%), GAAP EPS $12.11, non-GAAP EPS $17.69.
- FTC issued Second Request for Horizon acquisition, extending HSR waiting period 30 days after compliance.
- 2023 guidance provided excluding Horizon; free cash flow $8.8B for full year 2022.

## SEC filing metadata
- accession: 0000318154-23-000011
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2023-01-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815423000011/0000318154-23-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815423000011/amgn-20230130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-23-000011
- JSON: https://secwatch.observer/filing/0000318154-23-000011.json
- Plain text: https://secwatch.observer/filing/0000318154-23-000011.txt

## Key facts
- Earnings Releases
  AMGEN INC reported the three months ended December 31, 2022 results: revenue $6.8 billion, EPS $3.00.
  - Period: the three months ended December 31, 2022
  - Revenue: $6.8 billion
  - EPS: $3.00
  - Result: reported results
  source text: For the fourth quarter, total revenues were $6.8 billion, largely unchanged from Q4 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000031815423000011/0000318154-23-000011-index.htm
- Earnings Releases
  AMGEN INC reported the year ended December 31, 2022 results: revenue $26.3 billion, EPS $12.11.
  - Period: the year ended December 31, 2022
  - Revenue: $26.3 billion
  - EPS: $12.11
  - Result: reported results
  source text: For the full year, total revenues increased 1% to $26.3 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000031815423000011/0000318154-23-000011-index.htm
- Earnings Releases
  AMGEN INC updated its 2023 guidance (initiated).
  - Period: 2023
  - Guidance: initiated
  - Result: guidance update
  source text: AMGEN ALSO PROVIDES 2023 GUIDANCE EXCLUDING ANY CONTRIBUTION FROM THE ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000031815423000011/0000318154-23-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.